Projected Price to Earnings: NeuroSense Therapeutics Ltd. (NRSN)
The NeuroSense Therapeutics team leverages the expertise of leading neurobiologists, actively engaging specialized research coordinators. NeuroSense Therapeutics is developing PrimeC, an innovative drug to combat ALS that slows paralysis through a comprehensive impact on neurons. However, the risk of clinical trial failure remains high in a competitive race against industry behemoths. On GURU.Markets, the company's future P/E multiple clearly visualizes the cash flow, where the 0.00 level indicates the status of the parameter.
Analytical breakdowns and data insights for company NeuroSense Therapeutics, Ltd. (NRSN)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity NeuroSense Therapeutics|NRSN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital NeuroSense Therapeutics|NRSN - Company Cumulative Debt|Debt to Book Capitalization Ratio NeuroSense Therapeutics Ltd|NRSN - Company Long-Term Indebtedness|Company Short-Term Debt NeuroSense Therapeutics|Quick Ratio neurosense-tx.com
- company profitability and valuation multiples indicators:
NRSN - Company Net Income|Future Profit NeuroSense Therapeutics|NRSN - Company Value to Net Income|Projected Price to Earnings NeuroSense Therapeutics|NRSN - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple NeuroSense Therapeutics Ltd|NRSN - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) NeuroSense Therapeutics|NRSN - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months neurosense-tx.com|NRSN - Earnings per share increase in current year|Earnings growth forecast for next year NeuroSense Therapeutics
Analysis of all company metrics:NRSN NeuroSense Therapeutics Ltd.
To minimize risks when selecting growth assets, it is necessary to evaluate market expectations via the ratio of current capitalization to projected earnings. Analyzing the forward P/E of NeuroSense Therapeutics (NRSN) allows for the identification of management overvaluation, which is critical for NeuroSense Therapeutics (NRSN) as the future value of the business depends directly on the success of clinical trials for ALS drugs and the volume of R&D funding.
Who NeuroSense Therapeutics competes with
Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Regencell - Projected Price to Earnings|Forward P/E Multiple Axsome Corp AXSM|ACAD - Future Price to Earnings|Future Price to Earnings Multiple XENE (xenon-pharma.com)|Viking Therapeutics, Inc. (VKTX) - Future Price to Earnings|Projected Price to Earnings Ratio Supernus Pharmaceuticals, Inc. (SUPN)|Future Price to Earnings Catalyst Pharmaceuticals Inc|Denali Corp (DNLI) - Market Cap to Projected Earnings|Forward P/E Multiple HRMY|BHVN - Projected Price to Earnings Ratio|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Price to Future Earnings Ratio|PRAX - Future Price to Earnings|Market Cap to Projected Earnings Anavex Life Sciences Corp AVXL|CBLL: Forward P/E Multiple|Projected Price to Earnings Ratio Prothena (PRTA)|Projected Price to Earnings ALEC|ANNX: Future Price to Earnings Multiple|Projected Price to Earnings OMER (Omeros Corporation)|Market Cap to Future Earnings Ratio NGNE|Forward P/E Multiple ACIU (AC Immune)|Future Price to Earnings Multiple VYGR|Neumora Therapeutics, Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio Scilex Holding|Tevogen Bio Holdings, Inc. (TVGN) - Future Price to Earnings|Alpha Cognition Inc. - Future Price to Earnings Multiple|CGTX (Cognition Therapeutics) - Forward P/E Multiple|Forward P/E Multiple inhibikase.com|Future Price to Earnings Cassava Sciences (SAVA)|ASRT: Price to Expected Earnings Ratio|Forward P/E Multiple COYA (Coya Therapeutics)|VistaGen Therapeutics, Inc. (VTGN) - Projected Price to Earnings Ratio|OVID: Projected Price to Earnings|ABOS - Forward P/E Multiple|CRVO (CervoMed) - Projected Price to Earnings|ATHE: Market Cap to Future Earnings Ratio|CLNN (Clene Inc) - Forward P/E Multiple|PepGen Corp (PEPG) - Market Cap to Projected Earnings|Forward P/E Multiple JUNS|Projected Price to Earnings relmada.com RLMD|Future Price to Earnings Annovis Bio ANVS|Market Cap to Projected Earnings Grace Therapeutics Inc (GRCE)|AIFF - Future Price to Earnings|KLTO (Klotho Neurosciences Inc) - Price to Future Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|MetaVia - Future Price to Earnings Multiple|Future Price to Earnings NeurAxis|Helius Medical Technologies Inc. (HSDT) - Market Cap to Projected Earnings|Future Price to Earnings Passage Bio, Inc. (PASG)|bionomics.com.au - Price to Future Earnings Ratio|Future Price to Earnings Minerva Neurosciences NERV|ATHA: Price to Future Earnings Ratio|Addex Therapeutics Ltd - Forward P/E Multiple|Projected Price to Earnings Ratio Alzamend Neuro, Inc.|CYCN (cyclerion.com) - Projected Price to Earnings|Protagenic Therapeutics, Inc. (PTIX) - Forward P/E Multiple|Future Price to Earnings Pasithea Therapeutics Corp|CRGT: Future Price to Earnings Multiple|Future Price to Earnings Avenue Therapeutics, Inc. (ATXI)|BCLI - Projected Price to Earnings Ratio|Future Price to Earnings Cara Therapeutics, Inc CARA|CHRO: Price to Future Earnings Ratio|Eliem - Forward P/E Multiple|Projected Price to Earnings Ratio Intra-Cellular Therapies|LBPH (Longboard Pharmaceuticals, Inc.) - Projected Price to Earnings|Marinus Pharmaceuticals Inc (MRNS) - Forward P/E Multiple|Future Price to Earnings NKGen|NRBO: Future Price to Earnings Multiple|Future Price to Earnings Sage Therapeutics, Inc. (SAGE)|SNPX - Projected Price to Earnings Ratio|Future Price to Earnings Trevena TRVN|Market Cap to Projected Earnings Vigil Neuroscience Inc. (VIGL)|Anew Medical - Forward P/E Multiple|Projected Price to Earnings Ratio Cerevel Corp
